Gate Neurosciences is a biotechnology company specializing in synaptic health and focused on advancing next-generation precision treatments for central nervous system disorders. The company is dedicated to investigating and developing therapeutic targets related to synaptic function. Their lead program, zelquistinel, aims to address various CNS diseases, including depression and Alzheimer's cognition. Gate Neurosciences emphasizes the importance of dosing frequency in the effectiveness of their therapies.